These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25977839)

  • 1. Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.
    Young JW; Potter WZ; Riley S; Groeneveld GJ; Kinon BJ; Egan MF; Feltner DE
    Innov Clin Neurosci; 2015; 12(3-4):5S-10S. PubMed ID: 25977839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
    Busner J; Pandina G; Day S; Mahableshwarkar A; Kempf L; Sheean M; Dunn J
    Innov Clin Neurosci; 2023; 20(1-3):25-31. PubMed ID: 37122576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How modeling and simulation have enhanced decision making in new drug development.
    Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational PK/PD modeling to increase probability of success in drug discovery and early development.
    Lavé T; Caruso A; Parrott N; Walz A
    Drug Discov Today Technol; 2016; 21-22():27-34. PubMed ID: 27978984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of early efficacy endpoints for proof-of-concept trials.
    Chen C; Sun L; Li CL
    J Biopharm Stat; 2013 Mar; 23(2):413-24. PubMed ID: 23437947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.
    Szabo ST; Kinon BJ; Brannan SK; Krystal AK; van Gerven JM; Mahableshwarkar A; Sachs GS
    Innov Clin Neurosci; 2015; 12(3-4):11S-25S. PubMed ID: 25977837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic, translational, quantitative pain assessment tools in profiling of pain patients and for development of new analgesic compounds.
    Arendt-Nielsen L; Curatolo M
    Scand J Pain; 2013 Oct; 4(4):226-230. PubMed ID: 29913625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK.
    Cavero I
    Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development.
    Harvey PD; Busner J; Pandina G; Taylor HG; Grabb M; Jimenez-Shahed J
    Innov Clin Neurosci; 2023; 20(1-3):13-17. PubMed ID: 37122579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of Pediatric Initiatives on CNS Drug Development for All Ages-2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
    Pandina G; Busner J; Horrigan JP; McSherry C; Bateman-House A; Pani L; Kando J
    Innov Clin Neurosci; 2023; 20(1-3):18-24. PubMed ID: 37122578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.
    Greenhalgh AD; Ogungbenro K; Rothwell NJ; Galea JP
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):681-95. PubMed ID: 21521135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.